Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
May 14, 2024 08:00 ET
|
Belite Bio, Inc
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024 21:50 ET
|
Belite Bio, Inc
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024 08:00 ET
|
Belite Bio, Inc
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
May 08, 2024 08:00 ET
|
Belite Bio, Inc
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative...
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
May 06, 2024 08:15 ET
|
Belite Bio, Inc
Webinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m. ET Discussion will feature Dr. Michel Michaelides, leading expert in the field of inherited eye disease...
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
May 06, 2024 08:00 ET
|
Belite Bio, Inc
Additional analysis of visual acuity loss, genotypic profiles, and retinal imaging data from a 24-month Phase 2 trial of Tinlarebant in adolescent Stargardt disease patients provides further support...
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
May 01, 2024 16:15 ET
|
Belite Bio, Inc
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...
Belite Bio Announces $25 Million Registered Direct Offering
April 25, 2024 19:15 ET
|
Belite Bio, Inc
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel...
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
March 22, 2024 08:00 ET
|
Belite Bio, Inc
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
March 11, 2024 22:28 ET
|
Belite Bio, Inc
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...